Global Hairy Cell Leukemia Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|毛細胞白血病的全球市場(2021年∼2028年) Global Hairy Cell Leukemia Market - 2021-2028|
|出版日期: 2021年05月27日||內容資訊: 英文 180 Pages||
The global hairy cell leukemia market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Hairy cell leukemia is a rare type of cancer, which accounts for approximately 2% of all leukemia. Hairy cell leukemia is described by the uncontrolled growth of lymphocytes by the bone marrow. Hairy cell leukemia got its unique name from a morphology trait it displays. The excess B cells in hairy cell leukemia increase abnormal extensions and look hairy. With the rise in the number of leukemia cells, the amount of healthy white blood cells, red blood cells, and platelets in the body reduce significantly.
The risk factors for hairy cell leukemia treatment involve extended radiation exposure and certain agricultural and industrial chemicals. People of Ashkenazi Jewish ethnicity are also more susceptive to hairy cell leukemia than other groups. The diagnostic approached to distinguish hairy cell leukemia treatment include physical examination for increased spleen and lymph nodes, bone marrow biopsy, blood tests, imaging studies such as CT scan and tumor maker presence test.
The hairy cell leukemia market growth is driven by the rapid rise in the geriatric. The high number of rural inhabitants who experience greater exposure to fertilizer chemicals and better and quicker diagnostic techniques are likely to increase the number of hairy cell leukemia treatment patients.
Increase in diagnosis rates will drive the market growth
According to National Organization for Rare Disorders, approximately 600-800 new cases are diagnosed each year in the United States. Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect hairy cell leukemia. The first and foremost diagnostic test is a complete blood profile which indicates the total number of lymphocytes, which indicates the disease. Physicians can quickly diagnose if there is an enlarged spleen by physical examination. One important confirmation test is the presence of hairy cells in the blood in the lab tests. Most of the patients also require bone marrow biopsy for confirmation. The diagnosis rate of hairy cell leukemia has increased during the last two decades, which is expected to drive the market in the forecast period.
The persence of professional consultant hematologist is driving the market growth
The persence of professional consultant hematologists in the ruler and urban areas of developing developed and underdeveloped regions drive the global hairy cell leukemia market. The presence of diagnostic centers that play a vital role in detecting various types of leukemia is driving the market growth. The high number of rural inhabitants who experience greater exposure to fertilizer chemicals and better and quicker diagnostic techniques are likely to increase the number of hairy cell leukemia treatment patients.
Lack of awareness about such malignancies will hamper the market
However, lack of awareness about such malignancies and low efforts in research and development of novel treatment in hairy cell leukemia treatment is expected to restrain the market during the forecast period.
Treatment may not be required for people in the beginning stages of hairy cell leukemia. Because this cancer advances very gradually and sometimes doesn't progress at all, medication is often recommended only after signs and manifestations develop. The majority of patients with hairy cell leukemia eventually require treatment in the later stages. This factor will hamper the market growth.
COVID-19 Impact Analysis
The Hairy Cell Leukemia Foundation has recently gathered experts and discussed different clinical strategies for the supervision of COVID patients. The new recommendations modify the diagnosis and management of Hairy Cell Leukemia to the contemporary COVID-19 pandemic. A recent survey of the clinical course of patients with chronic lymphocytic leukemia who have COVID-19 reveals the high mortality linked with the need for hospitalization, improved patient age, and the number of co-morbid conditions.
At present, there are no renewed published data on the disease rates with COVID in Hairy Cell Leukemia patients. Experiences with the course of COVID-19 in Hairy Cell Leukemia patients are limited to case reports and individual communications. Despite this lack of evidence, Hairy Cell Leukemia patients and their treating physicians ask for guidance.
By therapy, the hairy cell leukemia Market is classified into targeted therapy, radiation therapy, immunotherapy, chemotherapy.
On the basis of therapy, the hairy cell leukemia Market is classified into targeted therapy radiation therapy, immunotherapy, chemotherapy.
The chemotherapy segment are expected to dominate the hairy cell leukemia Market during the forecast period
As per the American Cancer Society, there was throughout 22,840 death from hairy cell leukemia in 2019. Many companies focus on expanding breakthrough products to treat hairy cell leukemia to maintain their competing advantage and enter new regional markets. Chemotherapy drugs, especially purine analogs such as cladribine and pentostatin, are recognized as an initial treatment choice for most people with hairy cell leukemia. Additionally, the increase in funding for companies included in the research related to hairy cell leukemia is expected to drive the market growth in the forecast period.
Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.
While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.
North America region holds the largest market share in the global Hairy Cell Leukemia Market
North America region is dominating the global hairy cell leukemia market accounted for the largest market share in 2020, owing to the high incidence rate, increase in geriatric population and advancements in the treatment of hairy cell leukaemia. According to National Organization for Rare Disorders, Hairy cell leukemia is a rare type of blood cancer that affects about 6,000 persons in the United States.
The 2% of all hairy cell leukemia, with approx. 1000 new cases being recorded in the U.S each year. In the United States, a higher frequency of hairy cell leukemia is seen among white Americans than between African-Americans or Asians. Now a day next-generation sequencing is a gaining field in biomedical and healthcare research. This growing technology gives the roadmap for the researchers in the drug discovery and development of the hairy cell leukemia disorder.
On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.
The hairy cell leukemia market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis Inc, Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, and Celgene Corporation among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hairy cell leukemia market globally.
Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.
The global Hairy Cell Leukemia Market report would provide an access to an approx. 69 market data table, 65 figures and 200 pages.
LIST NOT EXHAUSTIVE